2021 -- H 5247 | |
======== | |
LC000175 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2021 | |
____________ | |
A N A C T | |
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT | |
| |
Introduced By: Representatives Amore, and Kazarian | |
Date Introduced: January 29, 2021 | |
Referred To: House Health & Human Services | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Sections 5-37.4-2 and 5-37.4-3 of the General Laws in Chapter 5-37.4 entitled |
2 | "Intractable Pain Treatment" are hereby amended to read as follows: |
3 | 5-37.4-2. Definitions. |
4 | For purposes of this chapter: |
5 | (1) "Chronic intractable pain" means pain that is: excruciating; constant; incurable, and of |
6 | such severity that it dominates virtually every conscious moment; produces mental and physical |
7 | debilitation; and may produce a desire to commit suicide for the sole purpose of stopping the pain. |
8 | A diagnosis and written documentation of chronic intractable pain made by a physician licensed in |
9 | the state of Rhode Island shall constitute proof that the patient suffers from chronic intractable pain. |
10 | (1)(2) "Director" means the director of the department of health of the state of Rhode |
11 | Island. |
12 | (2)(3) "Intractable pain" means a pain state that persists beyond the usual course of an acute |
13 | disease or healing of an injury or results from a chronic disease or condition that causes continuous |
14 | or intermittent pain over a period of months or years. Unless the context clearly indicates otherwise, |
15 | the term intractable pain includes chronic intractable pain. |
16 | (3)(4) "Practitioner" means health care professionals licensed to distribute, dispense, or |
17 | administer controlled substances in the course of professional practice as defined in § 21-28- |
18 | 1.02(41). |
19 | (4)(5) "Therapeutic purpose" means the use of controlled substances for the treatment of |
| |
1 | pain in appropriate doses as indicated by the patient's medical record. Any other use is |
2 | nontherapeutic. |
3 | 5-37.4-3. Controlled substances. |
4 | (a) A practitioner may prescribe, administer, or dispense controlled substances not |
5 | prohibited by law for a therapeutic purpose to a person diagnosed and treated by a practitioner for |
6 | a condition resulting in intractable pain, if this diagnosis and treatment has been documented in the |
7 | practitioner's medical records. No practitioner shall be subject to disciplinary action by the board |
8 | solely for prescribing, administering, or dispensing controlled substances when prescribed, |
9 | administered, or dispensed for a therapeutic purpose for a person diagnosed and treated by a |
10 | practitioner for a condition resulting in intractable pain, if this diagnosis and treatment has been |
11 | documented in the practitioner's medical records. |
12 | (b) The provisions of subsection (a) of this section do not apply to those persons being |
13 | treated by a practitioner for chemical dependency because of their use of controlled substances not |
14 | related to the therapeutic purposes of treatment of intractable pain. |
15 | (c) The provisions of subsection (a) of this section provide no authority to a practitioner to |
16 | prescribe, administer, or dispense controlled substances to a person the practitioner knows or should |
17 | know to be using the prescribed, administered, or dispensed controlled substance non- |
18 | therapeutically. |
19 | (d) Drug dependency or the possibility of drug dependency in and of itself is not a reason |
20 | to withhold or prohibit prescribing, administering, or dispensing controlled substances for the |
21 | therapeutic purpose of treatment of a person for intractable pain, nor shall dependency relating |
22 | solely to this prescribing, administering, or dispensing subject a practitioner to disciplinary action |
23 | by the director. |
24 | (e) Practitioners shall not refuse treatment consistent with federal or state laws, regulations |
25 | or guidelines for the prescribing of controlled substances under this chapter for the sole reason that |
26 | a patient requires intensive treatment. |
27 | (f) In coordination with §§ 21-28-3.20 and 21-28-3.20.1, the director of health may |
28 | promulgate rules and regulations necessary to effectuate the purpose of this chapter and ensure that |
29 | patients with intractable or chronic intractable pain are treated with dignity and not unduly denied |
30 | the medications needed to treat their conditions. |
31 | (g) Nothing in this section shall be construed to prohibit a practitioner or pharmacist from |
32 | denying a prescription based on their best clinical judgement. |
33 | (e)(h) Nothing in this section shall deny the right of the director to deny, revoke, or suspend |
34 | the license of any practitioner or discipline any practitioner who: |
| LC000175 - Page 2 of 7 |
1 | (1) Prescribes, administers, or dispenses a controlled substance that is nontherapeutic in |
2 | nature or nontherapeutic in the manner in which it is prescribed, administered, or dispensed, or fails |
3 | to keep complete and accurate on-going records of the diagnosis and treatment plan; |
4 | (2) Fails to keep complete and accurate records of controlled substances received, |
5 | prescribed, dispensed and administered, and disposal of drugs as required by law or of controlled |
6 | substances scheduled in the Comprehensive Drug Abuse Prevention and Control Act of 1970, 21 |
7 | U.S.C. § 801, et seq. A practitioner shall keep records of controlled substances received, prescribed, |
8 | dispensed and administered, and disposal of these drugs shall include the date of receipt of the |
9 | drugs, the sale or disposal of the drugs by the practitioner, the name and address of the person |
10 | receiving the drugs, and the reason for the disposal or the dispensing of the drugs to the person; |
11 | (3) Writes false or fictitious prescriptions for controlled substances as prohibited by law, |
12 | or for controlled substances scheduled in the Comprehensive Drug Abuse Prevention and Control |
13 | Act of 1970, 21 U.S.C § 801, et seq.; or |
14 | (4) Prescribes, administers, or dispenses in a manner which is inconsistent with provisions |
15 | of the law, or the Comprehensive Drug Abuse Prevention and Control Act of 1970, 21 U.S.C. § |
16 | 801, et seq., any controlled substance. |
17 | (f)(i) A practitioner may administer a controlled substance prescribed by a practitioner and |
18 | not prohibited by law for a therapeutic purpose to a person diagnosed and treated by a practitioner |
19 | for a condition resulting in intractable pain, if this diagnosis and treatment has been documented in |
20 | the practitioner's medical records. No practitioner shall be subject to disciplinary action by the |
21 | director solely for administering controlled substances when prescribed or dispensed for a |
22 | therapeutic purpose for a person diagnosed and treated by a practitioner for a condition resulting in |
23 | intractable pain, if this diagnosis and treatment has been documented in the practitioner's medical |
24 | records of the patient. |
25 | SECTION 2. Section 21-28-3.20 of the General Laws in Chapter 21-28 entitled "Uniform |
26 | Controlled Substances Act" is hereby amended to read as follows: |
27 | 21-28-3.20. Authority of practitioner to prescribe, administer, and dispense. |
28 | (a)(1) A practitioner, in good faith and in the course of his or her professional practice only, |
29 | may prescribe, administer, and dispense controlled substances, or he or she may cause the |
30 | controlled substances to be administered by a nurse or intern under his or her direction and |
31 | supervision. |
32 | (2) When issuing an initial prescription for an opiate to an adult patient, a practitioner shall |
33 | not exceed the maximum daily dose requirements established by the department of health. |
34 | (3) Except as provided in subsection (a)(4) of this section, a practitioner shall not issue an |
| LC000175 - Page 3 of 7 |
1 | opiate prescription to a minor for more than twenty (20) doses at any time. Prior to issuing an opiate |
2 | prescription to a minor, a practitioner shall discuss with the parent or guardian of the minor the |
3 | risks associated with opiate use and the reasons why the prescription is necessary. The practitioner |
4 | shall document his or her discussion with the parent or guardian in the medical record. |
5 | (4) Notwithstanding the limitations referenced in subsection (a)(3) of this section, if, in the |
6 | professional medical judgment of a practitioner, a greater dosage or supply of an opiate is required |
7 | to treat the minor patient's acute medical condition or is necessary for the treatment of chronic pain |
8 | management, sickle cell related pain, intractable pain treatment as defined in chapter 37.4 of title |
9 | 5, pain associated with a cancer diagnosis, or for palliative care, then the practitioner may issue a |
10 | prescription for the quantity needed to treat the acute medical condition, chronic pain, sickle cell |
11 | related pain, intractable pain, pain associated with a cancer diagnosis, or pain experienced while |
12 | the patient is in palliative care, provided that this dosage shall not exceed the maximum daily |
13 | dosage permitted for the treatment of this pain as set forth in the department of health regulations. |
14 | The condition triggering the prescription of an opiate shall be documented in the minor patient's |
15 | medical record, and the practitioner shall indicate that a non-opiate alternative was not appropriate |
16 | to address the medical condition. |
17 | (5) Notwithstanding subsections (a)(2) and (a)(3) of this section, this section shall not apply |
18 | to medications designed for the treatment of substance abuse or opioid dependence. |
19 | (b) The prescription-monitoring program shall be reviewed prior to starting any opioid. A |
20 | prescribing practitioner, or designee as authorized by § 21-28-3.32(a)(3), shall review the |
21 | prescription-monitoring program prior to refilling or initiating opioid therapy with an intrathecal |
22 | pump. For patients the prescribing practitioner is maintaining on continuous opioid therapy for pain |
23 | for three (3) months or longer, the prescribing practitioner shall review information from the |
24 | prescription-monitoring program at least every three (3) months. Documentation of that review |
25 | shall be noted in the patient's medical record. |
26 | (c) The director of health shall develop regulations for prescribing practitioners on |
27 | appropriate limits of opioid use in acute pain management. Initial prescriptions of opioids for acute |
28 | pain management of outpatient adults shall not exceed thirty (30) morphine milligram equivalents |
29 | (MMEs) total daily dose per day for a maximum total of twenty (20) doses, and, for pediatric |
30 | patients, the appropriate opioid dosage maximum per the department of health. |
31 | (d) For the purposes of this section, acute pain management shall not include chronic pain |
32 | management, pain associated with a cancer diagnosis, palliative or nursing home care, intractable |
33 | or chronic intractable pain, as provided in § 5-37.4-2, or other exception in accordance with |
34 | department of health regulations. |
| LC000175 - Page 4 of 7 |
1 | (e) Subsection (c) shall not apply to medications designed for the treatment of substance |
2 | abuse or opioid dependence. |
3 | (f) On or before September 1, 2018, the director of health shall develop, and make available |
4 | to healthcare practitioners, information on best practices for co-prescribing opioid antagonists to |
5 | patients. The best practices information shall identify situations in which co-prescribing an opioid |
6 | antagonist may be appropriate, including, but not limited to: |
7 | (1) In conjunction with a prescription for an opioid medication, under circumstances in |
8 | which the healthcare practitioner determines the patient is at an elevated risk for an opioid drug |
9 | overdose; |
10 | (2) In conjunction with medications prescribed pursuant to a course of medication therapy |
11 | management for the treatment of a substance use disorder involving opioids; or |
12 | (3) Under any other circumstances in which a healthcare practitioner identifies a patient as |
13 | being at an elevated risk for an opioid drug overdose. |
14 | (g) The best practices information developed pursuant to subsection (f) of this section shall |
15 | include guidelines for determining when a patient is at an elevated risk for an opioid drug overdose, |
16 | including, but not limited to, situations in which the patient: |
17 | (1) Meets the criteria provided in the opioid overdose toolkit published by the federal |
18 | substance abuse and mental health service administration; |
19 | (2) Is receiving high-dose, extended-release, or long-acting opioid medications; |
20 | (3) Has a documented history of an alcohol or substance use disorder, or a mental health |
21 | disorder; |
22 | (4) Has a respiratory ailment or other co-morbidity that may be exacerbated by the use of |
23 | opioid medications; |
24 | (5) Has a known history of intravenous drug use or misuse of prescription opioids; |
25 | (6) Has received emergency medical care or been hospitalized for an opioid overdose; or |
26 | (7) Uses opioids with antidepressants, benzodiazepines, alcohol, or other drugs. |
27 | (h) On or before September 1, 2018, the director of health and the secretary of the executive |
28 | office of health and human services shall develop strategies that include: |
29 | (1) Allowing practitioners in non-pharmacy settings to prescribe and dispense opioid |
30 | antagonists; and |
31 | (2) Ensuring that opioid antagonists that are distributed in a non-pharmacy setting are |
32 | eligible for reimbursement from any health insurance carrier, as defined under chapters 18, 19, 20, |
33 | and 41 of title 27, and the Rhode Island medical assistance program, as defined under chapter 7.2 |
34 | of title 42. |
| LC000175 - Page 5 of 7 |
1 | SECTION 3. Chapter 21-28 of the General Laws entitled "Uniform Controlled Substances |
2 | Act" is hereby amended by adding thereto the following section: |
3 | 21-28-3.20.1. Authority of practitioner to prescribe, administer, and dispense -- |
4 | Cancer, palliative care and chronic intractable pain. |
5 | (a) A practitioner, in good faith and in the course of his or her professional practice |
6 | managing pain associated with a cancer diagnosis, palliative or nursing home care, intractable or |
7 | chronic intractable pain as provided in § 5-37.4-2, or other condition allowed by department of |
8 | health regulations pursuant to the exception in § 21-28-3.20(d), may prescribe, administer, and |
9 | dispense controlled substances, or he or she may cause the controlled substances to be administered |
10 | by a nurse or intern under his or her direction and supervision without regard to the 2016 CDC |
11 | Guideline for Prescribing Opioids for Chronic Pain. |
12 | (b) Practitioners, in the course of their professional practice, shall not refuse treatment to |
13 | patients covered under this section for the sole reason that these patients require intensive treatment. |
14 | (c) The director of health may promulgate those rules and regulations necessary to |
15 | effectuate the provisions of this section and ensure that rules governing pain management |
16 | associated with a cancer diagnosis, palliative or nursing home care, intractable or chronic |
17 | intractable pain as provided in § 5-37.4-2, or other condition allowed by department of health |
18 | regulations pursuant to the exception created in § 21-28-3.20(d), shall: |
19 | (1) Take into consideration the individualized needs of patients covered by this section; |
20 | (2) Make provisions for practitioners, acting in good faith, and in the course of their |
21 | profession, and managing pain associated with their patients' illness to use their best judgment |
22 | notwithstanding any statute, rule or regulation to the contrary; and |
23 | (3) Ensure that patients covered by this section are treated with dignity and not unduly |
24 | denied the medications needed to treat their conditions. |
25 | SECTION 4. This act shall take effect upon passage. |
======== | |
LC000175 | |
======== | |
| LC000175 - Page 6 of 7 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT | |
*** | |
1 | This act would exclude chronic intractable pain from the definition of "acute pain |
2 | management", for purposes of prescribing, administering and dispensing controlled substances by |
3 | a practitioner. The act would prescribe new guidelines for the treatment of "chronic intractable |
4 | pain" based upon the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain. |
5 | This act would take effect upon passage. |
======== | |
LC000175 | |
======== | |
| LC000175 - Page 7 of 7 |